Drug Development Technology is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Most Read

  1. Tenapanor likely to makes waves in IBS-C space
  2. Stand Up To Cancer initiates ten clinical trial projects for oncology
  3. OncoArendi to evaluate OATD-01 in Phase I trial for asthma
  4. GSK’s Shingrix set to disrupt the herpes zoster vaccine marketplace
  5. Fulfilling the main unmet needs in prostate cancer will open the way for new ones

Latest Content

Tenapanor likely to makes waves in IBS-C space

On 11 October, Ardelyx reported positive results from a second pivotal Phase III trial (T3MPO-2) assessing the efficacy and safety of its lead product, tenapanor, which is under development for treatment of irritable bowel syndrome with constipation.

Benefits of Trehalose

Products such as monoclonal antibodies (mAb), fusion proteins, peptides, vaccines, antibody drug conjugulates (ADC) and stem cells benefit from the stabilising effects of Trehalose.

GSK’s Shingrix set to disrupt the herpes zoster vaccine marketplace

On September 13, GlaxoSmithKline (GSK) announced that the FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) voted unanimously to recommend the approval of its investigational vaccine, Shingrix (zoster vaccine, recombinant [adjuvanted]), for the prevention of herpes zoster (HZ) in adults ≥50 years of age.

Latest News

Read our magazine

Pharma Technology Focus is the essential reading material for decision-makers in the pharmaceutical industry, bringing you the latest news and analysis in an exciting, interactive format.

Send me notifications of new editions:

Go Top